§ Federal grant opportunity · PAR-27-025
Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Not Allowed)
National Institutes of Health is accepting applications for Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Not Allowed). The deadline is March 12, 2029 and the published award range is Award amount not published.
Key facts
- Funder
- National Institutes of Health
- Application deadline
- March 12, 2029
- Award range
- Award amount not published
- Eligibility
- Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- Geography
- United States
- Focus areas
- Health
- Opportunity number
- PAR-27-025
Program overview
The goal of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists trained in clinical and translational cancer research, and to promote their career development as cancer researchers. This Notice of Funding Opportunity (NOFO) does not allow Scholars to propose to lead an independent clinical trial, but does allow Scholars to propose research experience in a clinical trial led by a mentor or co-mentor.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from National Institutes of Health.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before March 12, 2029, allowing time for registration and validation.
Related grant opportunities
- Mathematical Sciences Research Institutes
- Science Track Award for Research Transition (START) Program (R03, Clinical Trial Optional)
- ARMY APPLICATIONS LAB BROAD AGENCY ANNOUNCEMENT FOR DISRUPTIVE APPLICATIONS
- NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)
- SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.